Back to top

Emerging Trends and Treatments for AUD

Share this on:

Alcohol use disorder is a complex and chronic condition that can be exacerbated by, basically, life. When life’s stressors pile up—as with the compounding uncertainty, isolation and loss experienced by many during the COVID pandemic—so does the susceptibility for finding relief or escape in substance use. What can we learn from the COVID experience about effective prevention, intervention and treatment of alcohol use disorder? And how can medications support and advance these efforts?

Join Hazelden Betty Ford’s chief medical officer, Alta DeRoo, MD, to take a closer look at the escalation of alcohol use and liver disease during the COVID pandemic. Dr. DeRoo will also review medications traditionally used in the treatment of alcohol use disorder and discuss emerging uses of other medications to reduce alcohol cravings and heavy drinking.

• Review the progression of alcohol use during the COVID pandemic
• Understand the impact of alcoholism on liver disease
• Identify FDA-approved medications for alcohol use disorder as well as emerging off-label uses


A board certified addiction medicine physician and obstetrician-gynecologist, Dr. DeRoo serves as chief medical officer of the Hazelden Betty Ford Foundation. She joined Hazelden Betty Ford in 2020 as medical director of the Betty Ford Center’s three facilities in California, located in Rancho Mirage, West Los Angeles and San Diego. Dr. DeRoo is a Distinguished Fellow of the American Society of Addiction Medicine and a member of the American Association of Addiction Psychiatry and the American College of Obstetricians and Gynecologists. Her extraordinary record of accomplishment includes a 24-year career in the U.S. Navy.

RSVP Required
Type of Event: 
Date & Time: 
Wednesday, November 30, 2022 1:30 pmADD TO YOUR CALENDAR